House Hopes To Cut FDA Bill Costs With Biosimilars Provision

Law360, New York (May 25, 2012, 5:08 PM EDT) -- House lawmakers moved quickly Thursday to prevent a possible roadblock to the U.S. Food and Drug Administration user fee bill, adding a new biosimilars provision that they hoped would cut the bill's costs before it comes up for a vote Wednesday.

The Congressional Budget Office, in a cost estimate released Thursday, found that the House version of the bill would increase budget deficits by $247 million over 10 years. Under House rules, bills that would increase the deficit must be offset by spending cuts or tax...
To view the full article, register now.